The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CSLL.Y | -37.31% | -39.46% | -9.54% | +551% |
| S&P | +19.89% | +109.18% | +15.89% | +748% |
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring and CSL Seqirus. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The CSL Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.
The company is facing being delisted from the S&P 600 Index.
Antibodies of recovered patients can help treat people who are infected with the novel coronavirus.
Currently no data to display
Currently no data to display.
Currently no data to display.
| Metric | YoY Change |
|---|
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
